البلد: هولندا
اللغة: الهولندية
المصدر: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
LAPATINIBDITOSILAAT 1-WATER 405 mg/stuk SAMENSTELLING overeenkomend met ; LAPATINIB 250 mg/stuk
LAPATINIBDITOSILAAT 1-WATER 405 mg/stuk SAMENSTELLING overeenkomend met ; LAPATINIB 250 mg/stuk
Filmomhulde tablet
CELLULOSE, MICROKRISTALLIJN (E 460(i)) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE GEEL (E 172) ; MACROGOL 400 ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMZETMEELGLYCOLAAT ; POLYSORBAAT 80 (E 433) ; POVIDON K 30 (E 1201) ; TITAANDIOXIDE (E 171), CELLULOSE, MICROKRISTALLIJN (E 460) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; IJZEROXIDE GEEL (E 172) ; MACROGOL 400 ; MAGNESIUMSTEARAAT (E 470b) ; NATRIUMZETMEELGLYCOLAAT ; POLYSORBAAT 80 (E 433) ; POVIDON K 30 (E 1201) ; TITAANDIOXIDE (E 171)
Oraal gebruik
1900-01-01
PACKAGE LEAFLET: INFORMATION FOR THE USER LAPATINIB PHAROS 250 MG, FILMOMHULDE TABLETTEN lapatinib READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Don’t pass it on to others. It may harm them, even if their signs of illness seem the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Lapatinib PharOS is and what it is used for 2. What you need to know before you take Lapatinib PharOS 3. How to take Lapatinib PharOS 4. Possible side effects 5. How to store Lapatinib PharOS 6. Contents of the pack and other information 1. WHAT LAPATINIB PHAROS IS AND WHAT IT IS USED FOR Lapatinib PharOS is used to treat certain types of breast cancer _(HER2-overexpressing) _ which have spread beyond the original tumour or to other organs ( _advanced _ or _metastatic _ breast cancer). It may slow or stop cancer cells from growing, or may kill them. Lapatinib PharOS is prescribed to be taken in combination with another anti-cancer medicine. Lapatinib PharOS is prescribed in COMBINATION WITH CAPECITABINE , for patients who have had treatment for advanced or metastatic breast cancer before. This previous treatment for metastatic breast cancer must have included trastuzumab. Lapatinib PharOS is prescribed in COMBINATION WITH TRASTUZUMAB , for patients who have hormone receptor- negative metastatic breast cancer and have had other treatment for advanced or metastatic breast cancer before. Lapatinib PharOS is prescribed in COMBINATION WITH AN AROMATASE INHIBITOR , for patients with hormone sensitive metastatic breast cancer (breast cancer that is more likely to grow in the presence of hormones), who are not currently intended for chemotherapy. In اقرأ الوثيقة كاملة
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lapatinib PharOS 250 mg, filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Oval, biconvex, off-white film-coated tablets debossed with “250” on one side and plain on the other, with dimensions of 16.6 mm x 8.3 mm ± 5%. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lapatinib PharOS is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2); • in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1). • in combination with trastuzumab for patients with hormone receptor-negative metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy (see section 5.1). • in combination with an aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor (see sections 4.4. and 5.1). No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Lapatinib PharOS treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal products. HER2 (ErbB2) overexpressing tumours are defined by IHC3+, or IHC2+ with gene amplification or gene amplification alone. HER2 status should be determined using accurate and validated methods. Posology _Lapatinib PharOS / capecitabine combination posology _ _ _ The re اقرأ الوثيقة كاملة